WO2019182131A1 - Medical device and method of applying medicament - Google Patents

Medical device and method of applying medicament Download PDF

Info

Publication number
WO2019182131A1
WO2019182131A1 PCT/JP2019/012162 JP2019012162W WO2019182131A1 WO 2019182131 A1 WO2019182131 A1 WO 2019182131A1 JP 2019012162 W JP2019012162 W JP 2019012162W WO 2019182131 A1 WO2019182131 A1 WO 2019182131A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
medicine
main body
wall
balloon
Prior art date
Application number
PCT/JP2019/012162
Other languages
French (fr)
Japanese (ja)
Inventor
ともみ 井上
隆 熊澤
雄紀 坂口
太輝人 犬飼
和俊 大橋
Original Assignee
テルモ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テルモ株式会社 filed Critical テルモ株式会社
Priority to JP2020507944A priority Critical patent/JP7214715B2/en
Publication of WO2019182131A1 publication Critical patent/WO2019182131A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00Dilators with or without means for introducing media, e.g. remedies

Definitions

  • the present invention relates to a medical device for applying a drug and a method for applying the drug.
  • Patent Document 1 a drug-coated balloon catheter used for applying a drug to a target site in a living body is known (for example, see Patent Document 1).
  • the drug-coated balloon catheter includes a long shaft and a balloon disposed at the tip of the shaft, and a drug is carried (held) on the outer surface of the balloon.
  • a surgeon such as a doctor delivers a balloon to a target site in the living body (for example, a treatment site of a biological lumen such as a blood vessel), and applies the drug to the blood vessel wall or the like by expanding the balloon at the target site. Take action.
  • a drug-coated balloon when the balloon is expanded, the drug is applied to the site that comes into contact with the outer surface of the balloon. There is a possibility of being applied.
  • the drug may fall off from the outer surface of the balloon, and the therapeutic effect of the drug may be reduced.
  • the amount of drug that can be applied in one treatment depends on the balloon length. Therefore, when the target site exists over a relatively wide range (for example, a relatively long range in the extending direction of the body lumen), it is necessary to perform a plurality of treatments using a plurality of drug-coating balloon catheters. is there. Therefore, the work burden required for the procedure is applied and the medical economy is reduced.
  • the drug for example, when the drug is a liquid or has a high viscosity, it may be difficult to coat the drug on the balloon. In such a case, it is necessary to give up application of the drug by the drug coating balloon catheter. However, depending on the target site, it may be difficult to eject the medicine (injection), so it may be necessary to abandon the application of the medicine itself.
  • the present invention has been made in view of the above problems, and can prevent the drug from dropping during delivery of the drug to the target site in the living body lumen, and the drug to the target site by a simple treatment. It is an object of the present invention to provide a medical device capable of selectively applying a drug and a method for applying a drug.
  • a medical device is provided between an inner wall portion that forms a lumen, an outer wall portion that forms an outer surface, and the inner wall portion and the outer wall portion, and holds a drug that is released in a living body lumen.
  • An elongate member comprising a body part having a possible drug holding part, a drug release part formed on the outer wall part and capable of releasing the drug from the drug holding part to the outer surface side, and the drug release part
  • An energy application unit that starts the release of the drug from the drug release unit by applying energy thereto.
  • the method for applying a medicine includes a step of providing a long member including a long main body portion in a state in which the medicine is held in a medicine holding portion provided between the inner wall portion and the outer wall portion; A step of preparing an energy applying unit capable of applying energy for starting the release of the drug from the drug holding unit, a step of introducing the main body into a body lumen, and a step of introducing the main body into the living body.
  • the energy application unit selectively applies energy to an arbitrary position of the main body unit to release the drug from the drug holding unit, and the biological tube Applying the medicine to the application target portion of the cavity.
  • the medical device and the method of applying the drug it is possible to prevent the drug from dropping out while delivering the drug to the target site in the living body lumen, and to select the drug for the target site by a simple treatment. It becomes possible to apply it.
  • FIG. 3 is a cross-sectional view taken along arrows 3A-3A in FIG. It is a flowchart which shows each procedure of the coating method of the chemical
  • FIGS. 5A to 5C are cross-sectional views schematically showing each procedure of the drug application method.
  • 6 (A) to 6 (C) are cross-sectional views schematically showing each procedure of the method of applying a medicine. It is sectional drawing which shows the modification 1 of embodiment.
  • FIG. 8 is a sectional view taken along arrows 8A-8A in FIG. FIG. 9A and FIG.
  • FIG. 9B are cross-sectional views for explaining a second modification of the embodiment.
  • FIG. 10A and FIG. 10B are cross-sectional views for explaining a third modification of the embodiment. It is sectional drawing for demonstrating the modification 4 of embodiment. It is sectional drawing for demonstrating the modification 5 of embodiment. It is a perspective view for demonstrating the modification 6 of embodiment. It is sectional drawing for demonstrating the modification 6 of embodiment.
  • the medical device 10 includes a catheter 100 (corresponding to “long member”) and a balloon catheter 200 (corresponding to “energy applying unit”).
  • the medical device 10 has a predetermined target site (application of a drug) in a blood vessel (corresponding to “biological lumen”) B. It is configured as a device for applying the drug 130 to the target site.
  • the living body lumen to which the drug is applied is not limited to blood vessels, and may be, for example, the bile duct, trachea, esophagus, other gastrointestinal tract, urethra, ear and nose lumen, and preferably coronary artery or lower limb artery It is.
  • the catheter 100 includes a long main body 110 having flexibility, and a hub 140 disposed on the proximal end side of the main body 110.
  • the side of the catheter 100 that is introduced into the living body is referred to as the “front end side”
  • the side on which the hub 140 is disposed is referred to as the “base end side”
  • the direction in which the main body 110 extends is referred to as an “axial direction”.
  • FIG. 2 shows a cross-sectional view (longitudinal cross-sectional view) near the tip of the main body 110.
  • FIG. 3 shows a cross-sectional view (transverse cross-sectional view) of a portion indicated by arrows 3A-3A in FIG.
  • the main body 110 of the catheter 100 is formed of a hollow tubular member.
  • the main body 110 of the catheter 100 includes an inner wall 121 that forms the lumen 111, an outer wall 123 that forms the outer surface of the main body 110, an inner wall 121 and an outer wall 123. And a drug holding part 125 that can hold the drug 130 released in the blood vessel B, and a drug release part that is formed on the outer wall part 123 and that can release the drug 130 from the drug holding part 125 to the outer surface side. 127.
  • a distal end opening 112 that communicates the lumen 111 with the outside is formed.
  • the medicine holding part 125 is configured by a space part that extends along the axial direction of the main body part 110 and is formed between the inner wall part 121 and the outer wall part 123.
  • the medicine holding part 125 is closed at the tip of the main body part 110.
  • the range (length in the axial direction) in which the medicine holding part 125 is formed in the axial direction of the main body 110 is not particularly limited.
  • a plurality of drug holding portions 125 may be provided at arbitrary positions in the axial direction of the main body 110 in a state where they are not in communication with each other.
  • the thickness (thickness on the cross section) of the medicine holding part 125 is not particularly limited.
  • the drug release part 127 is configured by a through hole formed in the outer wall part 123 so as to communicate the drug holding part 125 and the outer surface of the main body part 110.
  • the through hole may be formed over the entire circumference of the main body 110 or may be formed only in a part of the circumferential direction.
  • the cross-sectional shape and the number of through-holes constituting the medicine discharge portion 127, the interval between the through-holes in the axial direction of the main body 110, etc. are not particularly limited.
  • the diameter (hole diameter) of a through-hole is more than the molecular size of the chemical
  • the reason why such a dimension example is preferable is as follows. If the diameter of the through hole is excessively large, the medicine may be released from the through hole in a state where energy is not applied by the energy application unit 200. Further, if the diameter of the through hole is excessively small, it may be difficult to smoothly release the drug 130 through the through hole.
  • the specific dimension of the diameter of the through hole is not particularly limited as long as the drug 130 can be released when energy is applied by the energy application unit 200.
  • the specific configuration of the drug release unit 127 according to the present embodiment is not limited as long as the drug 130 can be released from the drug holding unit 125 to the outside as the balloon 210 is expanded.
  • the drug release part 127 may be configured by a mesh shape in which a small hole is formed, a semipermeable membrane that allows only the drug 130 to pass through, a rupture part (fragile part) that breaks when the balloon 210 is expanded, and the like. Is possible.
  • the main body 110 When the balloon 210 is expanded in the lumen 111 (see FIGS. 5C and 6B), the main body 110 deforms the inner wall 121 and the outer wall 123 and holds them in the medicine holding part 125. It is preferable to have a predetermined flexibility so that the drug 130 can be released from the drug release portion 127. From this point of view, the main body 110 (inner wall 121 and outer wall 123) is made of, for example, polyethylene, polypropylene, polyolefin of ethylene-propylene copolymer, polyester such as polyethylene terephthalate, polyvinyl chloride, ethylene-vinyl acetate copolymer.
  • the inner wall part 121 and the outer wall part 123 may not be the same, for example, the outer wall part 123 is comprised with a polyamide elastomer in order to maintain the shape of the chemical
  • it may be composed of silicone rubber or fluororubber.
  • the drug held in the drug holding unit 125 is not particularly limited as long as it is intended for application to a biological lumen such as the blood vessel B.
  • the medicine holding part 125 is configured by a closed space part formed between the inner wall part 121 and the outer wall part 123, the medicine holding part 125 can be used in the medicine holding part 125 regardless of the properties of the medicine.
  • the medicine 130 can be suitably held.
  • the properties of the drug 130 are widely selected from, for example, liquids, highly viscous liquids, gels, solids, powders, granules, water-soluble ones, fat-soluble ones, and any combination thereof. be able to.
  • the drug 130 include, for example, when the biological lumen to be applied is a blood vessel B, an anticancer agent, an immunosuppressive agent, an antibiotic, an antirheumatic agent, an antithrombotic agent, and an HMG-CoA reductase inhibitor.
  • Insulin resistance improver Insulin resistance improver, ACE inhibitor, calcium antagonist, antihyperlipidemic agent, integrin inhibitor, antiallergic agent, antioxidant, GP IIb / IIIa antagonist, retinoid, flavonoid, carotenoid, lipid improver DNA synthesis inhibitors, tyrosine kinase inhibitors, antiplatelet drugs, anti-inflammatory drugs, biological materials, interferons, nitric oxide production promoters, paclitaxel, docetaxel, sirolimus, everolimus, biolimus, zotarolimus, and the like.
  • the drug 130 may be filled in the drug holding unit 125 at a medical site (surgical site), for example.
  • a medical site surgical site
  • the medicine holding unit 125 is filled with the medicine 130 in the medical field, the medicine 130 that cannot be used due to the effect of EOG sterilization is used, or the medicine 130 with a short expiration date is used. Is also possible.
  • the configuration that does not particularly refer to the catheter 100 can be configured in the same manner as a known catheter device (for example, a microcatheter or a guide catheter) in the medical field, and detailed description thereof is omitted.
  • a known catheter device for example, a microcatheter or a guide catheter
  • the balloon catheter 200 starts the release of the drug 130 from the drug release unit 127 by applying energy to the main body 110 of the catheter 100 (see FIGS. 5C and 6B).
  • the balloon catheter 200 is composed of a rapid exchange type balloon catheter generally used in the medical field.
  • a balloon catheter 200 includes a balloon 210 that can be expanded and contracted as fluid flows in and out, a long shaft 220 having the balloon 210 disposed at the distal end, and a proximal end of the shaft 220. And a hub 230 disposed on the side.
  • the shaft 220 is provided with a guide wire port 225 for introducing the guide wire 300 into the lumen of the shaft 220.
  • the balloon catheter 200 can be inserted into the lumen 111 of the main body 110 of the catheter 100.
  • the balloon catheter 200 starts releasing the drug 130 from the drug discharge unit 127 when the balloon 210 is expanded while being inserted into the lumen 111.
  • the balloon 210 may have a protrusion or a reinforcing body for smoothly transferring the drug 130 from the drug holding part 125 to the outside or for breaking the outer wall part 123.
  • the specific configuration of the balloon catheter 200 is not particularly limited, and the balloon catheter 200 may be, for example, an over-the-wire type balloon catheter.
  • the method of applying the drug can be summarized as follows: a step of preparing a long member (S101), a step of preparing an energy application unit (S102), and a body portion of the long member as a body lumen.
  • An operator such as a doctor prepares the catheter 100 holding the medicine 130 in the medicine holding part 125 when starting the treatment for applying the medicine.
  • the surgeon prepares a balloon catheter 200 that is used to start the release of the drug 130 from the drug holding unit 125.
  • the surgeon introduces the main body 110 of the catheter 100 into the blood vessel B as shown in FIG.
  • the surgeon can appropriately use a medical instrument such as a guide wire or a guide catheter.
  • a medical instrument such as a guide wire or a guide catheter.
  • it may be introduced into the blood vessel B in a state where the balloon catheter 200 is inserted into the catheter 100 in advance and assembled.
  • the operator inserts the balloon catheter 200 into the lumen 111 of the main body 110 of the catheter 100 as shown in FIG.
  • the surgeon places the balloon 210 of the balloon catheter 200 at the target site (application target site) of the blood vessel B.
  • the operator can move the balloon catheter 200 along the guide wire 300 inserted into the lumen 111 of the main body 110 prior to the balloon catheter 200.
  • the surgeon introduces the body portion 110 of the catheter 100 into an arbitrary position (the purpose of the blood vessel B) with the balloon catheter 200 in a state where the body portion 110 is introduced into the blood vessel B.
  • Energy physical pressing force accompanying expansion of the balloon 210 is selectively applied to the periphery of the region.
  • the inner wall 121 and the outer wall 123 are deformed so as to approach each other as the balloon 210 is expanded.
  • the medicine holding part (space part) 125 formed between the inner wall part 121 and the outer wall part 123 is deformed so as to be crushed in a direction intersecting the axial direction when the inner wall part 121 and the outer wall part 123 approach each other. .
  • the drug 130 held in the drug holding part 125 is released to the outside through the drug release part 127 formed in the outer wall part 123 as the drug holding part 125 is deformed so as to be crushed. It is applied to the blood vessel wall.
  • the range where the drug 130 is applied in the blood vessel B (the length in the traveling direction of the blood vessel B) is within the range where the pressing force applied by the balloon 210 acts. Alternatively, once the necessary application is complete, the treatment may end here.
  • the surgeon contracts the balloon 210 as shown in FIG. After the balloon 210 is deflated, the surgeon moves the balloon 210 to the proximal end side with respect to the main body 110. Note that the surgeon may move the balloon 210 to the distal end side of the main body 110 together with the main body 110 when the target site to which the next medicine 130 is applied is the distal end side of the main body 110.
  • the surgeon expands the balloon 210 at a position different from the position described above (see FIG. 5C).
  • the balloon 210 applies energy to the main body 110 of the catheter 100 to release the drug 130 held by the drug holding part 125 to the outside through the drug release part 127 and apply it to the blood vessel wall of the blood vessel B.
  • the medicine 130 is applied to a target site different from the target site described above.
  • the surgeon contracts the balloon 210.
  • the surgeon removes the catheter 100 and the balloon catheter 200 from the living body.
  • the drug 130 is selectively applied to a portion of the blood vessel B corresponding to the portion to which energy is applied from the balloon 210.
  • the drug 130 can be applied over an arbitrary range of the blood vessel B by adjusting the position and number of times of expansion of the balloon 210.
  • the operator applies the drug 130 by expanding the balloon 210 twice, but the number of times the balloon 210 is expanded is not particularly limited as long as it is one or more times.
  • the balloon 210 is dilated so that the drug 130 is applied to a continuous position along the axial direction of the main body 110 of the catheter 100. There is no need to let them.
  • the operator may intermittently apply the drug 130 in the axial direction by expanding the balloon 210 a plurality of times at intervals in the axial direction of the main body 110 of the catheter 100.
  • the surgeon may perform a treatment to release the drug from the drug holding unit 125 more reliably by expanding the balloon 210 once and then expanding it again without shifting the position of the balloon 210. Good.
  • the operator prepares a plurality of types of balloon catheters having different lengths of the balloon 210, and each time the medicine 130 is applied, the balloon catheter is replaced to change the range of the medicine 130 to be applied. You may adjust.
  • the surgeon can also apply the drug 130 using a perfusion balloon catheter 200A (FIG. 12) described later in combination with the balloon catheter 200.
  • the medical device 10 is provided between the inner wall 121 that forms the lumen 111, the outer wall 123 that forms the outer surface, and the inner wall 121 and the outer wall 123.
  • a long portion having a medicine holding portion 125 capable of holding the medicine 130 released in B and a medicine releasing portion 127 formed on the outer wall portion 123 and capable of releasing the medicine 130 from the medicine holding portion 125 to the outer surface side.
  • a catheter 100 including a main body 110 and an energy application unit (balloon catheter) 200 for starting the release of the drug 130 from the drug release unit 127 by applying energy to the main body 110.
  • the operator selects the target site of the blood vessel B by a simple procedure of operating the energy application unit 200 and applying energy to the main body 110 of the catheter 100.
  • the drug 130 can be applied.
  • the catheter 100 can hold the drug 130 in the drug holding unit 125 until the energy applying unit 200 applies energy to the main body 110, the catheter 100 is being delivered to the target site of the blood vessel B.
  • the energy application unit 200 includes a balloon catheter that includes a balloon 210 that can be inserted into the lumen 111 of the main body 110 of the catheter 100 and that expands the lumen 111 to release the drug 130 from the drug discharge unit 127. . Therefore, the surgeon can selectively apply the medicine 130 to the target site by a simple operation of expanding the balloon 210 disposed in the lumen 111 of the main body 110. Moreover, since the medical device 10 can be comprised using the existing balloon catheter 200, the manufacturing cost of the medical device 10 can be reduced.
  • the medicine holding part 125 extends along the axial direction of the main body part 110 of the catheter 100 and has a space part formed between the inner wall part 121 and the outer wall part 123. Therefore, until the medicine 130 is applied to the blood vessel B, the medicine 130 is held so as not to be exposed to the outer surface of the main body 110. It is possible to more reliably prevent the main body 110 from falling off.
  • the drug release part 127 has a through hole formed in the outer wall part 123 so as to communicate the drug holding part 125 and the outer surface of the main body part 110. Therefore, the medicine release unit 127 can smoothly release the medicine 130 to the outside when the balloon 210 is expanded and receives a pressing force.
  • the drug application method includes a catheter 100 including a long main body 110 in a state where the drug 130 is held in a drug holding part 125 provided between the inner wall part 121 and the outer wall part 123.
  • the energy applying part 200 selectively applies energy to an arbitrary position of the main body part 110 of the catheter 100, thereby The step of applying the drug 130 to the target site (application target site) of the blood vessel B by releasing the drug 130 from 125. And, with a.
  • the surgeon operates the energy application unit 200 to selectively apply to the target site of the blood vessel B by a simple procedure of applying energy to the main body 110 of the catheter 100.
  • a drug 130 can be applied.
  • the catheter 100 can hold the drug 130 in the drug holding unit 125 until the energy applying unit 200 applies energy to the main body 110, the catheter 100 is being delivered to the target site of the blood vessel B.
  • the step of moving the energy application unit 200 relative to the medicine holding part 125 after the step of applying the medicine 130 is completed, and the catheter 100 is moved by the energy application part 200. Applying energy to the main body 110 and applying the drug 130 to a site different from the site where the drug 130 has already been applied.
  • the surgeon shifts the position of the energy application unit 200 and applies energy to the main body 110 of the catheter 100 a plurality of times, thereby causing the blood vessel B to move in the traveling direction.
  • the drug 130 can be applied over an arbitrary range. Therefore, for example, the surgeon can more reliably apply the medicine 130 to a lesioned part or the like that is formed long along the traveling direction of the blood vessel B.
  • the drug 130 is applied by inserting the balloon catheter 200 provided in the energy application unit into the lumen 111 of the main body 110 of the catheter 100 and then using the balloon 210 provided in the balloon catheter 200. Do this by expanding. Therefore, the surgeon can selectively apply the medicine 130 to the target site by a simple operation of expanding the balloon 210 disposed in the lumen 111 of the main body 110. In addition, since the medicine can be applied using the existing balloon catheter 200, the medical economy can be improved.
  • Modification 1 As shown in FIGS. 7 and 8, the main body 110 ⁇ / b> A according to Modification 1 includes a misalignment prevention unit 410 that prevents the medicine 130 held by the medicine holding unit 125 from being displaced.
  • the misalignment prevention unit 410 is configured by a partition wall formed between the inner wall 121 and the outer wall 123.
  • the misalignment prevention unit 410 can be formed over the entire circumference of the main body 110 ⁇ / b> A.
  • the shape, position, number, and the like of the misalignment prevention unit 410 are not particularly limited.
  • the misregistration prevention unit 410 may extend spirally in the drug holding unit 125. When the misregistration prevention unit 410 is formed in this manner, the misregistration prevention unit 410 can prevent the drug 130 from being misaligned in both the circumferential direction and the axial direction of the main body 110A.
  • the misalignment prevention unit 410 is accompanied by the movement of the balloon catheter 200 when the balloon catheter 200 inserted into the lumen 111 of the main body 110A is moved in the axial direction relative to the main body 110A. Prevents 130 from moving in the axial direction. Thereby, it can prevent that the chemical
  • the misalignment prevention unit 410 is made of a flexible resin material or the like so as not to hinder the deformation of the inner wall 121 when the balloon 210 is expanded in the lumen 111.
  • Modification 2 As shown in FIGS. 9A and 9B, the catheter according to Modification 2 is relatively movable along the axial direction of the main body 110 of the catheter, and the outer wall portion of the main body 110. 123, a masking member 510 that restricts the release of the drug 130 from the drug release portion 127 is provided.
  • the masking member 510 can be constituted by a hollow member that can slide with respect to the main body 110, for example. As shown in FIG. 9A, in a state where the masking member 510 covers the outer wall portion 123 and the drug release portion 127 from the outer surface side, even if the balloon 210 is expanded in the lumen 111, the drug release portion 127 The release of the drug 130 is limited. On the other hand, as shown in FIG. 9B, in a state where the masking member 510 is shifted in the axial direction of the main body portion 110 of the catheter 100 and a part of the outer wall portion 123 and the medicine discharge portion 127 are exposed from the masking member 510. By expanding the balloon 210, the drug 130 can be released from the drug release portion 127. As described above, by using the masking member 510, it is possible to control the portion to which the medicine 130 is applied more precisely.
  • the catheter main body 110 may be provided with a dedicated lumen for inserting the masking member 510 on the outer side of the outer wall portion 123, for example.
  • the drug 130 may be applied to a part of the circumference of the inner surface of the blood vessel by providing the masking member 510 on a part of the circumference.
  • the masking member 510 can be made of, for example, a known resin material or metal material.
  • the catheter according to the modified example 3 is a pushing assisting member 610 that assists pushing of the main body 110 when the main body 110 of the catheter is moved in the blood vessel B.
  • the pushing assisting member 610 can be formed of a hollow member that can slide with respect to the main body 110, for example. As shown in FIG. 10A, the rigidity of the main body 110 is reinforced by inserting the pushing assisting member 610 into the lumen 111 of the main body 110. Therefore, the pushing force of the main body 110 can be improved. The surgeon can smoothly move the main body 110 in the blood vessel B by improving the pushing force of the main body 110. In addition, the surgeon can prevent the main body 110 from being folded or kinked while moving the main body 110 in the blood vessel B. As shown in FIG. 10B, after delivering the catheter main body 110 to the target site of the blood vessel B, the pushing assisting member 610 is removed from the lumen 111. By removing the pushing assisting member 610, the surgeon can expand the balloon 210 within the lumen 111 to smoothly release the medicine 130.
  • the catheter body 110 may be provided with a dedicated lumen for inserting the push assisting member 610 inside the inner wall 121, for example.
  • the pushing assisting member 610 can be made of, for example, a known resin material or metal material.
  • the balloon catheter 200 can be used as a pushing assisting member that assists in the movement of the main body 110 of the catheter.
  • a pushing assisting member for example, a membrane material 710 for bringing the vicinity of the distal end of the balloon 210 into contact with the distal end of the main body 110 of the catheter can be attached.
  • the catheter main body 110 can be smoothly moved by pushing the balloon catheter 200 while the tip of the balloon 210 is in contact with the membrane material 710.
  • the film material 710 can be provided with a through-hole through which the guide wire 300 or the like is inserted. Further, the film material 710 can be made of, for example, a known resin material.
  • a so-called perfusion balloon catheter 200A can be used as a balloon catheter.
  • the perfusion balloon catheter 200A it becomes possible to secure blood flow while the balloon 210 is expanded and the drug 130 is applied, so that the drug 130 is applied to the target site of the blood vessel B. Can be continued for a long time. As a result, the drug 130 can be more reliably applied to the target site of the blood vessel B.
  • the perfusion balloon catheter 200A a known one in the medical field can be used.
  • FIGS. 13A and 13B are perspective views showing a state before and after the medicine is released from the slit 127 provided in the main body 110B.
  • 14A and 14B are cross-sectional views showing a state before and after the medicine is released from the slit 127 included in the main body 110B.
  • the main body 110B includes an inner wall 121, an outer wall 123, and a medicine holding part 125 formed between the inner wall 121 and the outer wall 123. And a slit 127 formed in the outer wall portion 123 so that the medicine holding portion 125 and the outer surface of the main body portion 110B can communicate with each other.
  • the slit 127 is formed in a part of the main body 110 in the axial direction. As shown in FIG. 14A, a plurality of slits 127 are formed at different positions in the circumferential direction of the main body 110. The position in the axial direction where the slits 127 are formed, the number of the slits 127, the interval in the circumferential direction of the slits 127, etc. are not particularly limited.
  • FIG. 13B and FIG. 14B show a state when the medicine 130 is released from the medicine holding part 125 by expanding a part of the main body part 110B.
  • the surgeon expands the slit 127 by expanding the balloon 210 (see FIGS. 5A and 5B) of the balloon catheter 200 within the lumen 111 of the main body 110B, thereby expanding the slit 127.
  • the medicine 130 held in the medicine holding part 125 can be released to the outside of the main body part 110B, and the surgeon has a slit 127 as shown in FIGS.
  • the medicine 130 held in the medicine holding part 125 can be prevented from leaking out from the main body part 110B, so that the surgeon moves the main body part 110B within a living body lumen such as a blood vessel. During this time, the medicine 130 can be prevented from being unintentionally applied to the patient.
  • the slit 127 should just be formed so that it can communicate with the outer wall part 123, and a part may be non-communication. Further, the slit 127 may be one that expands the balloon 210 to be opened and communicates.
  • the energy application unit is not limited to the balloon catheter.
  • energy such as pressure, electricity, ultrasonic waves, electromagnetic waves, heat, etc.
  • each of these energies is applied to the main body of the catheter simultaneously or with a time difference, etc.
  • a device configured to release the drug from The main body of the catheter can be appropriately modified in the form of the medicine holding part and the medicine releasing part according to the form of energy applied by the energy applying part.
  • the long member only needs to be a member that can be inserted into the living body lumen, and is not limited to the structure like the catheter described in the embodiment.
  • the medical device and the medicine application method according to the present invention have been described through the embodiment and a plurality of modified examples.
  • the present invention is not limited to the contents described in the embodiment and each modified example, and is claimed. It is possible to change appropriately based on the description of the range.
  • 10 medical devices 100 catheter (long member), 110, 110A body part, 111 lumens, 121 inner wall, 123 outer wall, 125 drug holder, 127 drug release part, 130 drugs, 200 balloon catheter (energy application part), 200A perfusion balloon catheter (energy application unit), 210 balloon, 220 shaft, 300 guidewire, 410 misalignment prevention unit, 510 masking member, 610 push-in auxiliary member, 710 membrane material, B Blood vessel (biological lumen).

Abstract

[Problem] To provide a medical device and a method of applying a medicament which are capable of preventing a medicament from being removed while delivering the medicament to a target site in a body lumen and of selectively applying the medicament to the target site by a simple procedure. [Solution] A medical device 10 that includes: a catheter 100 which has a long body portion 110 that includes an inner wall portion 121 that forms a lumen 111, an outer wall portion 123 that forms an outer surface, a medicament retaining portion 125 that is provided between the inner wall portion 121 and the outer wall portion 123 and is capable of retaining a medicament 130 to be released inside a blood vessel B, and a medicament releasing portion 127 that is formed on the outer wall portion and is capable of releasing the medicament from the medicament retaining portion toward the outer surface; and a balloon catheter 200 that initiates release of the medicament from the medicament releasing portion by applying energy to the body portion of the catheter.

Description

医療デバイス、および薬剤の塗布方法Medical device and method of applying drug
 本発明は、薬剤を塗布するための医療デバイス、および薬剤の塗布方法に関する。 The present invention relates to a medical device for applying a drug and a method for applying the drug.
 従来、生体内の目的部位に対して薬剤を塗布するために使用される薬剤コーティングバルーンカテーテルが知られている(例えば、特許文献1を参照)。 Conventionally, a drug-coated balloon catheter used for applying a drug to a target site in a living body is known (for example, see Patent Document 1).
 薬剤コーティングバルーンカテーテルは、長尺状のシャフトと、シャフトの先端部に配置されたバルーンと、を備えており、バルーンの外表面に薬剤が担持(保持)されている。医師等の術者は、バルーンを生体内の目的部位(例えば、血管等の生体管腔の治療部位)まで送達し、バルーンを目的部位において拡張させることにより、血管壁等に対して薬剤を塗布する処置を行う。 The drug-coated balloon catheter includes a long shaft and a balloon disposed at the tip of the shaft, and a drug is carried (held) on the outer surface of the balloon. A surgeon such as a doctor delivers a balloon to a target site in the living body (for example, a treatment site of a biological lumen such as a blood vessel), and applies the drug to the blood vessel wall or the like by expanding the balloon at the target site. Take action.
特開2013-192755号公報JP 2013-192755 A
 しかしながら、薬剤コーティングバルーンカテーテルを使用した処置では、例えば、下記のような課題が生じ得る。 However, in the treatment using the drug-coated balloon catheter, for example, the following problems can occur.
 薬剤コーティングバルーンでは、バルーンを拡張させた際に、バルーンの外表面と接触する部位に薬剤が塗布されてしまうため、本来的には薬剤の塗布を控えたい部位(正常な部位)にまで薬剤が塗布されてしまう可能性がある。 In a drug-coated balloon, when the balloon is expanded, the drug is applied to the site that comes into contact with the outer surface of the balloon. There is a possibility of being applied.
 また、薬剤コーティングバルーンカテーテルを目的部位まで送達している間に、バルーンの外表面から薬剤が脱落して、薬剤による治療効果等が低減する可能がある。 Also, while the drug-coated balloon catheter is being delivered to the target site, the drug may fall off from the outer surface of the balloon, and the therapeutic effect of the drug may be reduced.
 また、薬剤コーティグバルーンカテーテルを使用した処置では、一度の処置で塗布可能な薬剤の量がバルーン長に左右される。そのため、目的部位が比較的広い範囲(例えば、生体管腔の延伸方向の比較的長い範囲)に亘って存在する場合、複数の薬剤コーティグバルーンカテーテルを使用して、複数回の処置を行う必要がある。そのため、手技に要する作業負担が掛かるとともに、医療経済性が低下する。 Also, in treatment using a drug coated balloon catheter, the amount of drug that can be applied in one treatment depends on the balloon length. Therefore, when the target site exists over a relatively wide range (for example, a relatively long range in the extending direction of the body lumen), it is necessary to perform a plurality of treatments using a plurality of drug-coating balloon catheters. is there. Therefore, the work burden required for the procedure is applied and the medical economy is reduced.
 また、薬剤の性状によっては(例えば、薬剤が液体である場合や、高粘度である場合)、薬剤をバルーンにコーティングすることが難しい場合がある。そのような場合には、薬剤コーティグバルーンカテーテルによる薬剤の塗布を断念する必要がある。ただし、目的部位によっては薬剤の吐出(インジェクト)が困難な場合もあり得るため、薬剤の塗布自体を断念せざるを得ない場合もある。 Also, depending on the properties of the drug (for example, when the drug is a liquid or has a high viscosity), it may be difficult to coat the drug on the balloon. In such a case, it is necessary to give up application of the drug by the drug coating balloon catheter. However, depending on the target site, it may be difficult to eject the medicine (injection), so it may be necessary to abandon the application of the medicine itself.
 また、薬剤コーティングバルーンカテーテルの使用に関わらず、薬剤を簡便な処置(手順)により予防的に目的部位に塗布したいという要請もある。 There is also a demand for applying a drug to a target site prophylactically by a simple procedure (procedure) regardless of the use of a drug-coated balloon catheter.
 本発明は、上記課題に鑑みてなされたものであり、生体管腔の目的部位まで薬剤を送達する間に薬剤の脱落が生じることを防止でき、かつ、簡便な処置により目的部位に対して薬剤を選択的に塗布することが可能な医療デバイス、および薬剤の塗布方法を提供することを目的とする。 The present invention has been made in view of the above problems, and can prevent the drug from dropping during delivery of the drug to the target site in the living body lumen, and the drug to the target site by a simple treatment. It is an object of the present invention to provide a medical device capable of selectively applying a drug and a method for applying a drug.
 本発明に係る医療デバイスは、ルーメンを形成する内壁部と、外表面を形成する外壁部と、前記内壁部と前記外壁部との間に設けられ、生体管腔内で放出される薬剤を保持可能な薬剤保持部と、前記外壁部に形成され、前記薬剤を前記薬剤保持部から前記外表面側へ放出可能な薬剤放出部と、を有する本体部を備える長尺部材と、前記薬剤放出部に対してエネルギーを付与することにより、前記薬剤放出部からの前記薬剤の放出を開始させるエネルギー印加部と、を有する。 A medical device according to the present invention is provided between an inner wall portion that forms a lumen, an outer wall portion that forms an outer surface, and the inner wall portion and the outer wall portion, and holds a drug that is released in a living body lumen. An elongate member comprising a body part having a possible drug holding part, a drug release part formed on the outer wall part and capable of releasing the drug from the drug holding part to the outer surface side, and the drug release part An energy application unit that starts the release of the drug from the drug release unit by applying energy thereto.
 また、本発明に係る薬剤の塗布方法は、内壁部と外壁部との間に設けられた薬剤保持部に薬剤を保持した状態の長尺状の本体部を備える長尺部材を用意するステップと、前記薬剤保持部からの前記薬剤の放出を開始するためのエネルギーを付与可能なエネルギー印加部を用意するステップと、前記本体部を生体管腔内に導入するステップと、前記本体部を前記生体管腔内に導入した状態で、前記エネルギー印加部により、前記本体部の任意の位置に対して選択的にエネルギーを付与することにより、前記薬剤保持部から前記薬剤を放出させて、前記生体管腔の塗布対象部位に対して前記薬剤を塗布するステップと、を有する。 In addition, the method for applying a medicine according to the present invention includes a step of providing a long member including a long main body portion in a state in which the medicine is held in a medicine holding portion provided between the inner wall portion and the outer wall portion; A step of preparing an energy applying unit capable of applying energy for starting the release of the drug from the drug holding unit, a step of introducing the main body into a body lumen, and a step of introducing the main body into the living body. In the state introduced into the lumen, the energy application unit selectively applies energy to an arbitrary position of the main body unit to release the drug from the drug holding unit, and the biological tube Applying the medicine to the application target portion of the cavity.
 上記医療デバイスおよび上記薬剤の塗布方法によれば、生体管腔の目的部位まで薬剤を送達する間に薬剤の脱落が生じることを防止でき、かつ、簡便な処置により目的部位に対して薬剤を選択的に塗布することが可能になる。 According to the medical device and the method of applying the drug, it is possible to prevent the drug from dropping out while delivering the drug to the target site in the living body lumen, and to select the drug for the target site by a simple treatment. It becomes possible to apply it.
実施形態に係る医療デバイスを示す図である。It is a figure which shows the medical device which concerns on embodiment. 実施形態に係る長尺部材の本体部を示す断面図である。It is sectional drawing which shows the main-body part of the elongate member which concerns on embodiment. 図2の矢印3A-3Aに沿う断面図である。FIG. 3 is a cross-sectional view taken along arrows 3A-3A in FIG. 実施形態に係る薬剤の塗布方法の各手順を示すフローチャートである。It is a flowchart which shows each procedure of the coating method of the chemical | medical agent which concerns on embodiment. 図5(A)~(C)は、薬剤の塗布方法の各手順を模式的に示す断面図である。FIGS. 5A to 5C are cross-sectional views schematically showing each procedure of the drug application method. 図6(A)~(C)は、薬剤の塗布方法の各手順を模式的に示す断面図である。6 (A) to 6 (C) are cross-sectional views schematically showing each procedure of the method of applying a medicine. 実施形態の変形例1を示す断面図である。It is sectional drawing which shows the modification 1 of embodiment. 図7の矢印8A-8Aに沿う断面図である。FIG. 8 is a sectional view taken along arrows 8A-8A in FIG. 図9(A)、図9(B)は、実施形態の変形例2を説明するための断面図である。FIG. 9A and FIG. 9B are cross-sectional views for explaining a second modification of the embodiment. 図10(A)、図10(B)は、実施形態の変形例3を説明するための断面図である。FIG. 10A and FIG. 10B are cross-sectional views for explaining a third modification of the embodiment. 実施形態の変形例4を説明するための断面図である。It is sectional drawing for demonstrating the modification 4 of embodiment. 実施形態の変形例5を説明するための断面図である。It is sectional drawing for demonstrating the modification 5 of embodiment. 実施形態の変形例6を説明するための斜視図である。It is a perspective view for demonstrating the modification 6 of embodiment. 実施形態の変形例6を説明するための断面図である。It is sectional drawing for demonstrating the modification 6 of embodiment.
 以下、各図面を参照して、本発明の実施の形態を説明する。なお、図面の寸法比率は、説明の都合上誇張されており、実際の比率とは異なる場合がある。 Hereinafter, embodiments of the present invention will be described with reference to the drawings. In addition, the dimension ratio of drawing is exaggerated on account of description, and may differ from an actual ratio.
 図1に示すように、本実施形態に係る医療デバイス10は、カテーテル100(「長尺部材」に相当する)と、バルーンカテーテル200(「エネルギー印加部」に相当する)と、を備える。 As shown in FIG. 1, the medical device 10 according to the present embodiment includes a catheter 100 (corresponding to “long member”) and a balloon catheter 200 (corresponding to “energy applying unit”).
 図5(A)~(C)および図6(A)~(C)に示すように、医療デバイス10は、血管(「生体管腔」に相当する)Bの所定の目的部位(薬剤の塗布対象部位)に対して薬剤130を塗布するためのデバイスとして構成している。なお、薬剤を塗布する対象となる生体管腔は、血管に限定されず、例えば、胆管、気管、食道、その他消化管、尿道、耳鼻内腔等であってもよく、好ましくは冠動脈または下肢動脈である。 As shown in FIGS. 5 (A) to (C) and FIGS. 6 (A) to (C), the medical device 10 has a predetermined target site (application of a drug) in a blood vessel (corresponding to “biological lumen”) B. It is configured as a device for applying the drug 130 to the target site. The living body lumen to which the drug is applied is not limited to blood vessels, and may be, for example, the bile duct, trachea, esophagus, other gastrointestinal tract, urethra, ear and nose lumen, and preferably coronary artery or lower limb artery It is.
 (カテーテル)
 カテーテル100は、可撓性を備える長尺状の本体部110と、本体部110の基端側に配置されたハブ140と、を備える。なお、本明細書の説明において、カテーテル100の生体内に導入される側を「先端側」と称し、ハブ140が配置される側を「基端側」と称し、本体部110が延伸する方向(図1の左右方向)を「軸方向」と称する。
(catheter)
The catheter 100 includes a long main body 110 having flexibility, and a hub 140 disposed on the proximal end side of the main body 110. In the description of the present specification, the side of the catheter 100 that is introduced into the living body is referred to as the “front end side”, the side on which the hub 140 is disposed is referred to as the “base end side”, and the direction in which the main body 110 extends. (The left-right direction in FIG. 1) is referred to as an “axial direction”.
 図2には、本体部110の先端部付近の断面図(縦断面図)を示している。また、図3には、図2において矢印3A-3Aで示す部分の断面図(横断面図)を示している。 FIG. 2 shows a cross-sectional view (longitudinal cross-sectional view) near the tip of the main body 110. FIG. 3 shows a cross-sectional view (transverse cross-sectional view) of a portion indicated by arrows 3A-3A in FIG.
 カテーテル100の本体部110は、中空の管状部材で構成している。 The main body 110 of the catheter 100 is formed of a hollow tubular member.
 図2および図3に示すように、カテーテル100の本体部110は、ルーメン111を形成する内壁部121と、本体部110の外表面を形成する外壁部123と、内壁部121と外壁部123との間に設けられ、血管B内で放出される薬剤130を保持可能な薬剤保持部125と、外壁部123に形成され、薬剤130を薬剤保持部125から外表面側へ放出可能な薬剤放出部127と、を有している。 As shown in FIGS. 2 and 3, the main body 110 of the catheter 100 includes an inner wall 121 that forms the lumen 111, an outer wall 123 that forms the outer surface of the main body 110, an inner wall 121 and an outer wall 123. And a drug holding part 125 that can hold the drug 130 released in the blood vessel B, and a drug release part that is formed on the outer wall part 123 and that can release the drug 130 from the drug holding part 125 to the outer surface side. 127.
 カテーテル100の本体部110の先端には、ルーメン111と外部を連通する先端開口部112が形成されている。 At the distal end of the main body 110 of the catheter 100, a distal end opening 112 that communicates the lumen 111 with the outside is formed.
 薬剤保持部125は、本体部110の軸方向に沿って延在するとともに内壁部121と外壁部123との間に形成された空間部で構成している。薬剤保持部125は、本体部110の先端で閉じられている。 The medicine holding part 125 is configured by a space part that extends along the axial direction of the main body part 110 and is formed between the inner wall part 121 and the outer wall part 123. The medicine holding part 125 is closed at the tip of the main body part 110.
 薬剤保持部125が本体部110の軸方向に形成される範囲(軸方向の長さ)は特に限定されない。例えば、薬剤保持部125は、本体部110の軸方向の任意の箇所に、互いに連通していない状態で複数設けられていてもよい。また、薬剤保持部125の厚み(横断面上における厚み)も特に限定されない。 The range (length in the axial direction) in which the medicine holding part 125 is formed in the axial direction of the main body 110 is not particularly limited. For example, a plurality of drug holding portions 125 may be provided at arbitrary positions in the axial direction of the main body 110 in a state where they are not in communication with each other. Moreover, the thickness (thickness on the cross section) of the medicine holding part 125 is not particularly limited.
 薬剤放出部127は、薬剤保持部125と本体部110の外表面とを連通するように外壁部123に形成された貫通孔で構成している。貫通孔は、例えば、本体部110の周方向の全周に亘って形成してもよいし、周方向の一部のみに形成してもよい。また、薬剤放出部127を構成する貫通孔の断面形状、個数、本体部110の軸方向における貫通孔の間隔等は特に限定されない。 The drug release part 127 is configured by a through hole formed in the outer wall part 123 so as to communicate the drug holding part 125 and the outer surface of the main body part 110. For example, the through hole may be formed over the entire circumference of the main body 110 or may be formed only in a part of the circumferential direction. Further, the cross-sectional shape and the number of through-holes constituting the medicine discharge portion 127, the interval between the through-holes in the axial direction of the main body 110, etc. are not particularly limited.
 なお、薬剤放出部127が貫通孔で構成される場合、貫通孔の径(孔径)は、例えば、塗布する薬剤の分子サイズ以上、かつ、100μm以下であることが好ましい。このような寸法例が好ましい理由として、次のような点が挙げられる。貫通孔の径が過剰に大きいと、エネルギー印加部200によるエネルギーの付与を実施していない状態で貫通孔から薬剤が放出されてしまう可能性がある。また、貫通孔の径が過剰に小さいと、貫通孔を通して薬剤130を円滑に放出することが困難になる可能性がある。ただし、貫通孔の径の具体的な寸法は、エネルギー印加部200によりエネルギーを付与した際に、薬剤130を放出可能であれば、特に限定されない。 In addition, when the medicine discharge | release part 127 is comprised with a through-hole, it is preferable that the diameter (hole diameter) of a through-hole is more than the molecular size of the chemical | medical agent to apply | coat and 100 micrometers or less, for example. The reason why such a dimension example is preferable is as follows. If the diameter of the through hole is excessively large, the medicine may be released from the through hole in a state where energy is not applied by the energy application unit 200. Further, if the diameter of the through hole is excessively small, it may be difficult to smoothly release the drug 130 through the through hole. However, the specific dimension of the diameter of the through hole is not particularly limited as long as the drug 130 can be released when energy is applied by the energy application unit 200.
 本実施形態に係る薬剤放出部127は、バルーン210の拡張に伴って薬剤130を薬剤保持部125から外部へ放出可能であれば具体的な構成は限定されない。例えば、薬剤放出部127は、細径な孔が形成されたメッシュ状、薬剤130のみを透過する半透膜、バルーン210の拡張に伴って破断する破断部(脆弱部)等で構成することも可能である。 The specific configuration of the drug release unit 127 according to the present embodiment is not limited as long as the drug 130 can be released from the drug holding unit 125 to the outside as the balloon 210 is expanded. For example, the drug release part 127 may be configured by a mesh shape in which a small hole is formed, a semipermeable membrane that allows only the drug 130 to pass through, a rupture part (fragile part) that breaks when the balloon 210 is expanded, and the like. Is possible.
 本体部110は、ルーメン111内においてバルーン210を拡張させた際(図5(C)、図6(B)を参照)、内壁部121および外壁部123を変形させて薬剤保持部125に保持した薬剤130を薬剤放出部127から放出させることが可能となるように所定の可撓性を備えることが好ましい。このような観点より、本体部110(内壁部121および外壁部123)は、例えば、ポリエチレン、ポリプロピレン、エチレン-プロピレン共重合体のポリオレフィン、ポリエチレンテレフタレート等のポリエステル、ポリ塩化ビニル、エチレン-酢酸ビニル共重合体、架橋型エチレン-酢酸ビニル共重合体、ポリウレタン等の熱可塑性樹脂、ポリアミド、ポリアミドエラストマー、ポリスチレンエラストマー、シリコーンゴム、ラテックスゴム等の材料で構成することができる。あるいは、内壁部121と外壁部123の材料は同一でなくてもよく、例えば、外壁部123は薬剤放出部127の形状を維持するためにポリアミドエラストマーで構成し、内壁部121は伸縮可能となるようにシリコーンゴムまたはフッ素ゴムで構成してもよい。 When the balloon 210 is expanded in the lumen 111 (see FIGS. 5C and 6B), the main body 110 deforms the inner wall 121 and the outer wall 123 and holds them in the medicine holding part 125. It is preferable to have a predetermined flexibility so that the drug 130 can be released from the drug release portion 127. From this point of view, the main body 110 (inner wall 121 and outer wall 123) is made of, for example, polyethylene, polypropylene, polyolefin of ethylene-propylene copolymer, polyester such as polyethylene terephthalate, polyvinyl chloride, ethylene-vinyl acetate copolymer. It can be made of a material such as a polymer, a crosslinked ethylene-vinyl acetate copolymer, a thermoplastic resin such as polyurethane, a polyamide, a polyamide elastomer, a polystyrene elastomer, a silicone rubber, or a latex rubber. Or the material of the inner wall part 121 and the outer wall part 123 may not be the same, for example, the outer wall part 123 is comprised with a polyamide elastomer in order to maintain the shape of the chemical | medical agent discharge | release part 127, and the inner wall part 121 becomes extensible. Thus, it may be composed of silicone rubber or fluororubber.
 薬剤保持部125において保持される薬剤は、血管B等の生体管腔への塗布を目的とするものであれば特に限定されない。本実施形態において、薬剤保持部125は、内壁部121と外壁部123との間に形成された閉じられた空間部で構成されているため、薬剤の性状を問わずに薬剤保持部125内において薬剤130を好適に保持することができる。薬剤130の性状は、例えば、液体、高粘性の液体、ゲル、固体、粉体、粒状物、水溶性のもの、脂溶性のもの、およびこれらの中から任意に組み合わされるもの等、幅広く選択することができる。 The drug held in the drug holding unit 125 is not particularly limited as long as it is intended for application to a biological lumen such as the blood vessel B. In this embodiment, since the medicine holding part 125 is configured by a closed space part formed between the inner wall part 121 and the outer wall part 123, the medicine holding part 125 can be used in the medicine holding part 125 regardless of the properties of the medicine. The medicine 130 can be suitably held. The properties of the drug 130 are widely selected from, for example, liquids, highly viscous liquids, gels, solids, powders, granules, water-soluble ones, fat-soluble ones, and any combination thereof. be able to.
 薬剤130の具体的な種類としては、例えば、塗布対象となる生体管腔が血管Bである場合、抗癌剤、免疫抑制剤、抗生物質、抗リウマチ剤、抗血栓薬、HMG-CoA還元酵素阻害剤、インスリン抵抗性改善剤、ACE阻害剤、カルシウム拮抗剤、抗高脂血症薬、インテグリン阻害薬、抗アレルギー剤、抗酸化剤、GP IIb/IIIa拮抗薬、レチノイド、フラボノイド、カロチノイド、脂質改善薬、DNA合成阻害剤、チロシンキナーゼ阻害剤、抗血小板薬、抗炎症薬、生体由来材料、インターフェロン、一酸化窒素産生促進物質、パクリタキセル、ドセタキセル、シロリムス、エベロリムス、バイオリムス、ゾタロリムス等を挙げることができる。 Specific examples of the drug 130 include, for example, when the biological lumen to be applied is a blood vessel B, an anticancer agent, an immunosuppressive agent, an antibiotic, an antirheumatic agent, an antithrombotic agent, and an HMG-CoA reductase inhibitor. , Insulin resistance improver, ACE inhibitor, calcium antagonist, antihyperlipidemic agent, integrin inhibitor, antiallergic agent, antioxidant, GP IIb / IIIa antagonist, retinoid, flavonoid, carotenoid, lipid improver DNA synthesis inhibitors, tyrosine kinase inhibitors, antiplatelet drugs, anti-inflammatory drugs, biological materials, interferons, nitric oxide production promoters, paclitaxel, docetaxel, sirolimus, everolimus, biolimus, zotarolimus, and the like.
 なお、薬剤130は、例えば、医療現場(手術現場)において薬剤保持部125に充填するようにしてもよい。カテーテル100の製品出荷段階においては、EOG滅菌等を施すことが必要になり、また、出荷から使用までの間の期間が長期間に亘ることも考えられる。例えば、医療現場において薬剤保持部125へ薬剤130を充填するようにすれば、EOG滅菌の影響で使用不可になるような薬剤130を使用したり、使用期限が短い薬剤130を使用したりすることも可能になる。 Note that the drug 130 may be filled in the drug holding unit 125 at a medical site (surgical site), for example. At the product shipping stage of the catheter 100, it is necessary to perform EOG sterilization or the like, and the period from shipment to use may be long. For example, if the medicine holding unit 125 is filled with the medicine 130 in the medical field, the medicine 130 that cannot be used due to the effect of EOG sterilization is used, or the medicine 130 with a short expiration date is used. Is also possible.
 カテーテル100について特に言及しない構成については、医療分野において公知のカテーテルデバイス(例えば、マイクロカテーテルやガイドカテーテル)と同様に構成することができ、その詳細な説明は省略する。 The configuration that does not particularly refer to the catheter 100 can be configured in the same manner as a known catheter device (for example, a microcatheter or a guide catheter) in the medical field, and detailed description thereof is omitted.
 (バルーンカテーテル)
 バルーンカテーテル200は、カテーテル100の本体部110に対してエネルギーを付与することにより、薬剤放出部127からの薬剤130の放出を開始させる(図5(C)および図6(B)を参照)。
(Balloon catheter)
The balloon catheter 200 starts the release of the drug 130 from the drug release unit 127 by applying energy to the main body 110 of the catheter 100 (see FIGS. 5C and 6B).
 バルーンカテーテル200は、医療分野において一般的に使用されるラピッドエクスチェンジ型のバルーンカテーテルで構成している。 The balloon catheter 200 is composed of a rapid exchange type balloon catheter generally used in the medical field.
 図1に示すように、バルーンカテーテル200は、流体の流入および排出に伴って拡張収縮可能なバルーン210と、バルーン210が先端部に配置された長尺状のシャフト220と、シャフト220の基端側に配置されたハブ230と、を備える。シャフト220には、シャフト220のルーメン内にガイドワイヤ300を導入するためのガイドワイヤポート225が設けられている。 As shown in FIG. 1, a balloon catheter 200 includes a balloon 210 that can be expanded and contracted as fluid flows in and out, a long shaft 220 having the balloon 210 disposed at the distal end, and a proximal end of the shaft 220. And a hub 230 disposed on the side. The shaft 220 is provided with a guide wire port 225 for introducing the guide wire 300 into the lumen of the shaft 220.
 図5(B)および図5(C)に示すように、バルーンカテーテル200は、カテーテル100の本体部110のルーメン111内に挿入可能である。バルーンカテーテル200は、ルーメン111内に挿入された状態でバルーン210が拡張されることにより、薬剤放出部127からの薬剤130の放出を開始させる。 As shown in FIG. 5B and FIG. 5C, the balloon catheter 200 can be inserted into the lumen 111 of the main body 110 of the catheter 100. The balloon catheter 200 starts releasing the drug 130 from the drug discharge unit 127 when the balloon 210 is expanded while being inserted into the lumen 111.
 バルーンカテーテル200の手元付近(基端部付近)には、バルーン210を血管Bの目的部位に対して正確に位置合わせするためのマーカー等を設けてもよい。また、バルーン210は、薬剤130を薬剤保持部125から外部へ円滑に移行させたり、外壁部123を破断させたりするための突起や補強体を有するように構成してもよい。 Near the hand of the balloon catheter 200 (near the base end), a marker or the like for accurately positioning the balloon 210 with respect to the target site of the blood vessel B may be provided. The balloon 210 may have a protrusion or a reinforcing body for smoothly transferring the drug 130 from the drug holding part 125 to the outside or for breaking the outer wall part 123.
 バルーンカテーテル200の具体的な構成は特に限定されず、バルーンカテーテル200は、例えば、オーバーザワイヤ型のバルーンカテーテルであってもよい。 The specific configuration of the balloon catheter 200 is not particularly limited, and the balloon catheter 200 may be, for example, an over-the-wire type balloon catheter.
 (処置方法)
 次に、図4~図6を参照して、本実施形態に係る薬剤の塗布方法を説明する。
(Treatment method)
Next, a method for applying a medicine according to the present embodiment will be described with reference to FIGS.
 図4に示すように、薬剤の塗布方法は、概説すると、長尺部材を準備する工程(S101)と、エネルギー印加部を準備する工程(S102)と、長尺部材の本体部を生体管腔内に導入する工程(S103)と、エネルギー印加部を長尺部材に挿入する工程(S104)と、薬剤を塗布する工程(S105)と、エネルギー印加部を移動させる工程(S106)と、薬剤を塗布する工程(S107)と、を有する。 As shown in FIG. 4, the method of applying the drug can be summarized as follows: a step of preparing a long member (S101), a step of preparing an energy application unit (S102), and a body portion of the long member as a body lumen. A step (S103) of introducing the energy application unit into the elongated member (S104), a step of applying a drug (S105), a step of moving the energy application unit (S106), Applying (S107).
 医師等の術者は、薬剤を塗布する処置を開始するにあたり、薬剤保持部125には薬剤130が保持されたカテーテル100を準備する。また、術者は、薬剤保持部125から薬剤130の放出を開始させるために使用されるバルーンカテーテル200を準備する。 An operator such as a doctor prepares the catheter 100 holding the medicine 130 in the medicine holding part 125 when starting the treatment for applying the medicine. In addition, the surgeon prepares a balloon catheter 200 that is used to start the release of the drug 130 from the drug holding unit 125.
 次に、術者は、図5(A)に示すように、カテーテル100の本体部110を血管B内に導入する。術者は、カテーテル100を血管B内に導入する際、ガイドワイヤやガイドカテーテル等の医療器具を適宜使用することができる。あるいは、予め体外でカテーテル100にバルーンカテーテル200を挿入して組み立てた状態で、血管B内に導入してもよい。 Next, the surgeon introduces the main body 110 of the catheter 100 into the blood vessel B as shown in FIG. When introducing the catheter 100 into the blood vessel B, the surgeon can appropriately use a medical instrument such as a guide wire or a guide catheter. Alternatively, it may be introduced into the blood vessel B in a state where the balloon catheter 200 is inserted into the catheter 100 in advance and assembled.
 次に、術者は、図5(B)に示すように、カテーテル100の本体部110のルーメン111内にバルーンカテーテル200を挿入する。術者は、バルーンカテーテル200のバルーン210を血管Bの目的部位(塗布対象部位)に配置する。術者は、バルーンカテーテル200をカテーテル100内に挿入する際、バルーンカテーテル200に先立って本体部110のルーメン111内に挿入されたガイドワイヤ300に沿ってバルーンカテーテル200を移動させることができる。 Next, the operator inserts the balloon catheter 200 into the lumen 111 of the main body 110 of the catheter 100 as shown in FIG. The surgeon places the balloon 210 of the balloon catheter 200 at the target site (application target site) of the blood vessel B. When inserting the balloon catheter 200 into the catheter 100, the operator can move the balloon catheter 200 along the guide wire 300 inserted into the lumen 111 of the main body 110 prior to the balloon catheter 200.
 次に、術者は、図5(C)に示すように、カテーテル100の本体部110を血管B内に導入した状態で、バルーンカテーテル200により、本体部110の任意の位置(血管Bの目的部位周辺)に対して選択的にエネルギー(バルーン210の拡張に伴う物理的な押圧力)を付与する。内壁部121と外壁部123は、バルーン210の拡張に伴って互いに接近するように変形する。内壁部121と外壁部123の間に形成された薬剤保持部(空間部)125は、内壁部121と外壁部123が接近することにより、軸方向と交差する方向に押し潰されるように変形する。薬剤保持部125に保持された薬剤130は、薬剤保持部125が押し潰されるように変形するのに伴って外壁部123に形成された薬剤放出部127を介して外部に放出され、血管Bの血管壁に塗布される。血管Bにおいて薬剤130が塗布される範囲(血管Bの走行方向における長さ)は、バルーン210が付与する押圧力が作用する範囲内に収められる。あるいは、必要なところの塗布が完了すれば、ここで、治療を終えてもよい。 Next, as shown in FIG. 5 (C), the surgeon introduces the body portion 110 of the catheter 100 into an arbitrary position (the purpose of the blood vessel B) with the balloon catheter 200 in a state where the body portion 110 is introduced into the blood vessel B. Energy (physical pressing force accompanying expansion of the balloon 210) is selectively applied to the periphery of the region. The inner wall 121 and the outer wall 123 are deformed so as to approach each other as the balloon 210 is expanded. The medicine holding part (space part) 125 formed between the inner wall part 121 and the outer wall part 123 is deformed so as to be crushed in a direction intersecting the axial direction when the inner wall part 121 and the outer wall part 123 approach each other. . The drug 130 held in the drug holding part 125 is released to the outside through the drug release part 127 formed in the outer wall part 123 as the drug holding part 125 is deformed so as to be crushed. It is applied to the blood vessel wall. The range where the drug 130 is applied in the blood vessel B (the length in the traveling direction of the blood vessel B) is within the range where the pressing force applied by the balloon 210 acts. Alternatively, once the necessary application is complete, the treatment may end here.
 次に、術者は、図6(A)に示すように、バルーン210を収縮させる。術者は、バルーン210を収縮させた後、バルーン210を本体部110に対して基端側へ移動させる。なお、術者は、次の薬剤130を塗布する目的部位が本体部110の先端側である場合には、本体部110とともに、バルーン210を本体部110の先端側に移動させてもよい。 Next, the surgeon contracts the balloon 210 as shown in FIG. After the balloon 210 is deflated, the surgeon moves the balloon 210 to the proximal end side with respect to the main body 110. Note that the surgeon may move the balloon 210 to the distal end side of the main body 110 together with the main body 110 when the target site to which the next medicine 130 is applied is the distal end side of the main body 110.
 次に、術者は、図6(B)に示すように、バルーン210を前述した位置(図5(C)を参照)とは異なる位置で拡張させる。バルーン210は、カテーテル100の本体部110に対してエネルギーを付与することにより、薬剤保持部125に保持された薬剤130を薬剤放出部127を介して外部に放出し、血管Bの血管壁に付与する。薬剤130は、前述した目的部位とは異なる目的部位に対して塗布される。 Next, as shown in FIG. 6B, the surgeon expands the balloon 210 at a position different from the position described above (see FIG. 5C). The balloon 210 applies energy to the main body 110 of the catheter 100 to release the drug 130 held by the drug holding part 125 to the outside through the drug release part 127 and apply it to the blood vessel wall of the blood vessel B. To do. The medicine 130 is applied to a target site different from the target site described above.
 次に、術者は、バルーン210を収縮させる。術者は、バルーン210を収縮させた後、カテーテル100およびバルーンカテーテル200を生体外へ抜去する。図6(C)に示すように、バルーン210を拡張させた際に、血管Bにおいてバルーン210からエネルギーが付与された部分に対応する箇所には、薬剤130が選択的に塗布される。このように、医療デバイス10を使用した薬剤130の塗布方法では、バルーン210を拡張させる位置や回数等を調整することにより、血管Bの任意の範囲に亘って薬剤130を塗布することができる。 Next, the surgeon contracts the balloon 210. After the balloon 210 is deflated, the surgeon removes the catheter 100 and the balloon catheter 200 from the living body. As shown in FIG. 6C, when the balloon 210 is expanded, the drug 130 is selectively applied to a portion of the blood vessel B corresponding to the portion to which energy is applied from the balloon 210. As described above, in the method of applying the drug 130 using the medical device 10, the drug 130 can be applied over an arbitrary range of the blood vessel B by adjusting the position and number of times of expansion of the balloon 210.
 なお、上述した実施形態では、術者は、バルーン210を2回拡張させることにより薬剤130の塗布を行ったが、バルーン210を拡張させる回数は1回以上であれば特に限定されない。 In the above-described embodiment, the operator applies the drug 130 by expanding the balloon 210 twice, but the number of times the balloon 210 is expanded is not particularly limited as long as it is one or more times.
 また、術者は、一度の処置で複数回に亘ってバルーン210を拡張する場合、カテーテル100の本体部110の軸方向に沿って連続的な位置に薬剤130を塗布するようにバルーン210を拡張させる必要はない。例えば、術者は、カテーテル100の本体部110の軸方向において間隔を空けてバルーン210を複数回に亘って拡張させることにより、薬剤130を軸方向に断続的に塗布してもよい。 Further, when the surgeon dilates the balloon 210 multiple times in one treatment, the balloon 210 is dilated so that the drug 130 is applied to a continuous position along the axial direction of the main body 110 of the catheter 100. There is no need to let them. For example, the operator may intermittently apply the drug 130 in the axial direction by expanding the balloon 210 a plurality of times at intervals in the axial direction of the main body 110 of the catheter 100.
 また、術者は、例えば、バルーン210を一度拡張させた後に、バルーン210の位置をずらすことなく再度拡張させることにより、薬剤保持部125からより確実に薬剤を放出させるように処置を行ってもよい。 Further, for example, the surgeon may perform a treatment to release the drug from the drug holding unit 125 more reliably by expanding the balloon 210 once and then expanding it again without shifting the position of the balloon 210. Good.
 また、術者は、バルーン210の長さ等が異なる複数の品種のバルーンカテーテルを準備しておき、薬剤130の塗布を実施する都度、バルーンカテーテルを入れ替えることにより、薬剤130を塗布する範囲等を調整してもよい。また、術者は、後述するパフュージョンバルーンカテーテル200A(図12)をバルーンカテーテル200と併用して薬剤130の塗布を実施することも可能である。 In addition, the operator prepares a plurality of types of balloon catheters having different lengths of the balloon 210, and each time the medicine 130 is applied, the balloon catheter is replaced to change the range of the medicine 130 to be applied. You may adjust. The surgeon can also apply the drug 130 using a perfusion balloon catheter 200A (FIG. 12) described later in combination with the balloon catheter 200.
 以上のように、本実施形態に係る医療デバイス10は、ルーメン111を形成する内壁部121と、外表面を形成する外壁部123と、内壁部121と外壁部123との間に設けられ、血管B内で放出される薬剤130を保持可能な薬剤保持部125と、外壁部123に形成され、薬剤130を薬剤保持部125から外表面側へ放出可能な薬剤放出部127と、を有する長尺状の本体部110を備えるカテーテル100と、本体部110に対してエネルギーを付与することにより、薬剤放出部127からの薬剤130の放出を開始させるエネルギー印加部(バルーンカテーテル)200と、を有する。 As described above, the medical device 10 according to the present embodiment is provided between the inner wall 121 that forms the lumen 111, the outer wall 123 that forms the outer surface, and the inner wall 121 and the outer wall 123. A long portion having a medicine holding portion 125 capable of holding the medicine 130 released in B and a medicine releasing portion 127 formed on the outer wall portion 123 and capable of releasing the medicine 130 from the medicine holding portion 125 to the outer surface side. A catheter 100 including a main body 110 and an energy application unit (balloon catheter) 200 for starting the release of the drug 130 from the drug release unit 127 by applying energy to the main body 110.
 本実施形態に係る医療デバイス10によれば、術者は、エネルギー印加部200を操作してカテーテル100の本体部110に対してエネルギーを付与する簡便な処置により血管Bの目的部位に対して選択的に薬剤130を塗布することができる。また、カテーテル100は、エネルギー印加部200が本体部110に対してエネルギーを付与するまでの間、薬剤保持部125において薬剤130を保持することができるため、血管Bの目的部位に送達さている間に薬剤130が脱落するのを好適に防止することができる。 According to the medical device 10 according to the present embodiment, the operator selects the target site of the blood vessel B by a simple procedure of operating the energy application unit 200 and applying energy to the main body 110 of the catheter 100. In particular, the drug 130 can be applied. Further, since the catheter 100 can hold the drug 130 in the drug holding unit 125 until the energy applying unit 200 applies energy to the main body 110, the catheter 100 is being delivered to the target site of the blood vessel B. In addition, it is possible to suitably prevent the medicine 130 from falling off.
 また、エネルギー印加部200は、カテーテル100の本体部110のルーメン111内に挿入可能であるとともにルーメン111内において拡張することにより薬剤放出部127から薬剤130を放出させるバルーン210を備えるバルーンカテーテルを有する。そのため、術者は、本体部110のルーメン111内に配置したバルーン210を拡張させる簡単な作業により、目的部位に対して選択的に薬剤130を塗布することができる。また、既存のバルーンカテーテル200を利用して医療デバイス10を構成することができるため、医療デバイス10の製造コストを削減することができる。 The energy application unit 200 includes a balloon catheter that includes a balloon 210 that can be inserted into the lumen 111 of the main body 110 of the catheter 100 and that expands the lumen 111 to release the drug 130 from the drug discharge unit 127. . Therefore, the surgeon can selectively apply the medicine 130 to the target site by a simple operation of expanding the balloon 210 disposed in the lumen 111 of the main body 110. Moreover, since the medical device 10 can be comprised using the existing balloon catheter 200, the manufacturing cost of the medical device 10 can be reduced.
 また、薬剤保持部125は、カテーテル100の本体部110の軸方向に沿って延在するとともに内壁部121と外壁部123との間に形成された空間部を有する。そのため、薬剤130は血管Bに塗布されるまでの間、本体部110の外表面に晒されることのないように保持されるため、カテーテル100を血管B内で送達している間に薬剤130が本体部110から脱落するのをより確実に防止することができる。 Moreover, the medicine holding part 125 extends along the axial direction of the main body part 110 of the catheter 100 and has a space part formed between the inner wall part 121 and the outer wall part 123. Therefore, until the medicine 130 is applied to the blood vessel B, the medicine 130 is held so as not to be exposed to the outer surface of the main body 110. It is possible to more reliably prevent the main body 110 from falling off.
 また、薬剤放出部127は、薬剤保持部125と本体部110の外表面とを連通するように外壁部123に形成された貫通孔を有する。そのため、薬剤放出部127は、バルーン210が拡張して押圧力を受けた際に、薬剤130を外部へ円滑に放出することができる。 Also, the drug release part 127 has a through hole formed in the outer wall part 123 so as to communicate the drug holding part 125 and the outer surface of the main body part 110. Therefore, the medicine release unit 127 can smoothly release the medicine 130 to the outside when the balloon 210 is expanded and receives a pressing force.
 また、本実施形態に係る薬剤の塗布方法は、内壁部121と外壁部123との間に設けられた薬剤保持部125に薬剤130を保持した状態の長尺状の本体部110を備えるカテーテル100を用意するステップと、薬剤保持部125からの薬剤130の放出を開始するためのエネルギーを付与可能なエネルギー印加部200を用意するステップと、カテーテル100の本体部110を血管B内に導入するステップと、カテーテル100の本体部110を血管B内に導入した状態で、エネルギー印加部200により、カテーテル100の本体部110の任意の位置に対して選択的にエネルギーを付与することにより、薬剤保持部125から薬剤130を放出させて、血管Bの目的部位(塗布対象部位)に対して薬剤130を塗布するステップと、を有する。 In addition, the drug application method according to this embodiment includes a catheter 100 including a long main body 110 in a state where the drug 130 is held in a drug holding part 125 provided between the inner wall part 121 and the outer wall part 123. Preparing an energy application unit 200 capable of applying energy for starting the release of the drug 130 from the drug holding unit 125, and introducing the main body 110 of the catheter 100 into the blood vessel B. In the state where the main body part 110 of the catheter 100 is introduced into the blood vessel B, the energy applying part 200 selectively applies energy to an arbitrary position of the main body part 110 of the catheter 100, thereby The step of applying the drug 130 to the target site (application target site) of the blood vessel B by releasing the drug 130 from 125. And, with a.
 上記の薬剤の塗布方法によれば、術者は、エネルギー印加部200を操作してカテーテル100の本体部110に対してエネルギーを付与する簡便な処置により血管Bの目的部位に対して選択的に薬剤130を塗布することができる。また、カテーテル100は、エネルギー印加部200が本体部110に対してエネルギーを付与するまでの間、薬剤保持部125において薬剤130を保持することができるため、血管Bの目的部位に送達さている間に薬剤130が脱落するのを好適に防止することができる。 According to the medicine application method described above, the surgeon operates the energy application unit 200 to selectively apply to the target site of the blood vessel B by a simple procedure of applying energy to the main body 110 of the catheter 100. A drug 130 can be applied. Further, since the catheter 100 can hold the drug 130 in the drug holding unit 125 until the energy applying unit 200 applies energy to the main body 110, the catheter 100 is being delivered to the target site of the blood vessel B. In addition, it is possible to suitably prevent the medicine 130 from falling off.
 また、本実施形態に係る薬剤の塗布方法は、薬剤130を塗布するステップを終えた後にエネルギー印加部200を薬剤保持部125に対して相対的に移動させるステップと、エネルギー印加部200によりカテーテル100の本体部110に対してエネルギーを付与し、既に薬剤130を塗布した部位とは異なる部位に対して薬剤130を塗布するステップと、を有する。 In addition, in the medicine application method according to the present embodiment, the step of moving the energy application unit 200 relative to the medicine holding part 125 after the step of applying the medicine 130 is completed, and the catheter 100 is moved by the energy application part 200. Applying energy to the main body 110 and applying the drug 130 to a site different from the site where the drug 130 has already been applied.
 上記の薬剤の塗布方法によれば、術者は、エネルギー印加部200の位置をずらして複数回に亘ってカテーテル100の本体部110に対してエネルギーを付与することにより、血管Bの走行方向における任意の範囲に亘って薬剤130を塗布することができる。そのため、術者は、例えば、血管Bの走行方向に沿って長く形成された病変部等に対して薬剤130をより確実に塗布することが可能になる。 According to the medicine application method described above, the surgeon shifts the position of the energy application unit 200 and applies energy to the main body 110 of the catheter 100 a plurality of times, thereby causing the blood vessel B to move in the traveling direction. The drug 130 can be applied over an arbitrary range. Therefore, for example, the surgeon can more reliably apply the medicine 130 to a lesioned part or the like that is formed long along the traveling direction of the blood vessel B.
 また、本実施形態に係る薬剤の塗布方法において、薬剤130の塗布は、エネルギー印加部が備えるバルーンカテーテル200をカテーテル100の本体部110のルーメン111内に挿入し、バルーンカテーテル200が備えるバルーン210を拡張させることにより行う。そのため、術者は、本体部110のルーメン111内に配置したバルーン210を拡張させる簡単な作業により、目的部位に対して選択的に薬剤130を塗布することができる。また、既存のバルーンカテーテル200を利用して薬剤の塗布を実施することができるため、医療経済性の向上を図ることができる。 In the drug application method according to the present embodiment, the drug 130 is applied by inserting the balloon catheter 200 provided in the energy application unit into the lumen 111 of the main body 110 of the catheter 100 and then using the balloon 210 provided in the balloon catheter 200. Do this by expanding. Therefore, the surgeon can selectively apply the medicine 130 to the target site by a simple operation of expanding the balloon 210 disposed in the lumen 111 of the main body 110. In addition, since the medicine can be applied using the existing balloon catheter 200, the medical economy can be improved.
 次に、変形例に係る医療デバイスを説明する。前述した実施形態と同一の構成については、同一の符号を付し、その説明を省略する。また、変形例の説明において特に言及しない構成や処置手順については、前述した実施形態と実質的に同一に構成することができるものとする。 Next, a medical device according to a modification will be described. The same components as those in the above-described embodiment are denoted by the same reference numerals, and the description thereof is omitted. In addition, configurations and treatment procedures that are not particularly mentioned in the description of the modified example can be configured substantially the same as those of the above-described embodiment.
 (変形例1)
 図7および図8に示すように、変形例1に係る本体部110Aは、薬剤保持部125に保持された薬剤130が位置ずれするのを防止する位置ずれ防止部410を有している。
(Modification 1)
As shown in FIGS. 7 and 8, the main body 110 </ b> A according to Modification 1 includes a misalignment prevention unit 410 that prevents the medicine 130 held by the medicine holding unit 125 from being displaced.
 位置ずれ防止部410は、内壁部121と外壁部123との間に形成された隔壁で構成している。位置ずれ防止部410は、例えば、図8に示すように、本体部110Aの周方向の全周に亘って形成することができる。ただし、位置ずれ防止部410の形状、位置、個数等は特に限定されない。例えば、位置ずれ防止部410は、薬剤保持部125内においてらせん状に延在していてもよい。このように位置ずれ防止部410が形成される場合、位置ずれ防止部410により、薬剤130が本体部110Aの周方向および軸方向の両方向に位置ずれするのを防止することが可能になる。 The misalignment prevention unit 410 is configured by a partition wall formed between the inner wall 121 and the outer wall 123. For example, as shown in FIG. 8, the misalignment prevention unit 410 can be formed over the entire circumference of the main body 110 </ b> A. However, the shape, position, number, and the like of the misalignment prevention unit 410 are not particularly limited. For example, the misregistration prevention unit 410 may extend spirally in the drug holding unit 125. When the misregistration prevention unit 410 is formed in this manner, the misregistration prevention unit 410 can prevent the drug 130 from being misaligned in both the circumferential direction and the axial direction of the main body 110A.
 位置ずれ防止部410は、本体部110Aのルーメン111内に挿入したバルーンカテーテル200を、本体部110Aに対して相対的に軸方向に移動させる際などに、バルーンカテーテル200の移動に同伴して薬剤130が軸方向に移動するのを防止する。これにより、薬剤130が薬剤保持部125内において、先端側や基端側に片寄って配置されるのを防止することができる。 The misalignment prevention unit 410 is accompanied by the movement of the balloon catheter 200 when the balloon catheter 200 inserted into the lumen 111 of the main body 110A is moved in the axial direction relative to the main body 110A. Prevents 130 from moving in the axial direction. Thereby, it can prevent that the chemical | medical agent 130 is offset and arrange | positioned in the chemical | medical agent holding | maintenance part 125 at the front end side or the base end side.
 なお、位置ずれ防止部410は、ルーメン111内でバルーン210を拡張させた際に内壁部121の変形を阻害することのないように、柔軟な樹脂材料等で構成することが好ましい。 In addition, it is preferable that the misalignment prevention unit 410 is made of a flexible resin material or the like so as not to hinder the deformation of the inner wall 121 when the balloon 210 is expanded in the lumen 111.
 (変形例2)
 図9(A)および図9(B)に示すように、変形例2に係るカテーテルは、カテーテルの本体部110の軸方向に沿って相対的に移動可能であるとともに、本体部110の外壁部123を覆うように配置されることにより、薬剤放出部127からの薬剤130の放出を制限するマスキング部材510を有する。
(Modification 2)
As shown in FIGS. 9A and 9B, the catheter according to Modification 2 is relatively movable along the axial direction of the main body 110 of the catheter, and the outer wall portion of the main body 110. 123, a masking member 510 that restricts the release of the drug 130 from the drug release portion 127 is provided.
 マスキング部材510は、例えば、本体部110に対して摺動可能な中空状の部材で構成することができる。図9(A)に示すように、マスキング部材510が外壁部123および薬剤放出部127を外表面側から覆った状態では、ルーメン111内でバルーン210を拡張させたとしても、薬剤放出部127からの薬剤130の放出が制限される。一方、図9(B)に示すように、マスキング部材510をカテーテル100の本体部110の軸方向にずらして、一部の外壁部123および薬剤放出部127をマスキング部材510から露出させた状態では、バルーン210を拡張させることにより、薬剤放出部127から薬剤130を放出させることができる。このように、マスキング部材510を利用することにより、薬剤130が塗布される部位をより精密に制御することが可能になる。 The masking member 510 can be constituted by a hollow member that can slide with respect to the main body 110, for example. As shown in FIG. 9A, in a state where the masking member 510 covers the outer wall portion 123 and the drug release portion 127 from the outer surface side, even if the balloon 210 is expanded in the lumen 111, the drug release portion 127 The release of the drug 130 is limited. On the other hand, as shown in FIG. 9B, in a state where the masking member 510 is shifted in the axial direction of the main body portion 110 of the catheter 100 and a part of the outer wall portion 123 and the medicine discharge portion 127 are exposed from the masking member 510. By expanding the balloon 210, the drug 130 can be released from the drug release portion 127. As described above, by using the masking member 510, it is possible to control the portion to which the medicine 130 is applied more precisely.
 なお、カテーテルの本体部110には、例えば、外壁部123の外側にマスキング部材510を挿入するための専用のルーメンを設けることも可能である。また、マスキング部材510を円周上の一部に設けることで、血管内面の円周上の一部に薬剤130を塗布してもよい。 Note that the catheter main body 110 may be provided with a dedicated lumen for inserting the masking member 510 on the outer side of the outer wall portion 123, for example. In addition, the drug 130 may be applied to a part of the circumference of the inner surface of the blood vessel by providing the masking member 510 on a part of the circumference.
 マスキング部材510は、例えば、公知の樹脂材料や金属材料で構成することができる。 The masking member 510 can be made of, for example, a known resin material or metal material.
 (変形例3)
 図10(A)および図10(B)に示すように、変形例3に係るカテーテルは、カテーテルの本体部110を血管B内において移動させる際に本体部110の押し込みを補助する押込補助部材610を有する。
(Modification 3)
As shown in FIGS. 10 (A) and 10 (B), the catheter according to the modified example 3 is a pushing assisting member 610 that assists pushing of the main body 110 when the main body 110 of the catheter is moved in the blood vessel B. Have
 押込補助部材610は、例えば、本体部110に対して摺動可能な中空状の部材で構成することができる。図10(A)に示すように、押込補助部材610を本体部110のルーメン111内に挿入することにより、本体部110の剛性が補強される。そのため、本体部110の押し込み力を向上させることができる。術者は、本体部110の押し込み力が向上されることにより、本体部110を血管B内で円滑に移動させることができる。また、術者は、本体部110を血管B内で移動させている間に、本体部110に折れやキンクが発生するのを防止することができる。図10(B)に示すように、血管Bの目的部位までカテーテルの本体部110を送達した後、押込補助部材610はルーメン111から抜去する。術者は、押込補助部材610を抜去することにより、ルーメン111内でバルーン210を拡張させて薬剤130を円滑に放出させることが可能になる。 The pushing assisting member 610 can be formed of a hollow member that can slide with respect to the main body 110, for example. As shown in FIG. 10A, the rigidity of the main body 110 is reinforced by inserting the pushing assisting member 610 into the lumen 111 of the main body 110. Therefore, the pushing force of the main body 110 can be improved. The surgeon can smoothly move the main body 110 in the blood vessel B by improving the pushing force of the main body 110. In addition, the surgeon can prevent the main body 110 from being folded or kinked while moving the main body 110 in the blood vessel B. As shown in FIG. 10B, after delivering the catheter main body 110 to the target site of the blood vessel B, the pushing assisting member 610 is removed from the lumen 111. By removing the pushing assisting member 610, the surgeon can expand the balloon 210 within the lumen 111 to smoothly release the medicine 130.
 なお、カテーテルの本体部110には、例えば、内壁部121の内側に押込補助部材610を挿入するための専用のルーメンを設けることも可能である。 The catheter body 110 may be provided with a dedicated lumen for inserting the push assisting member 610 inside the inner wall 121, for example.
 押込補助部材610は、例えば、公知の樹脂材料や金属材料で構成することができる。 The pushing assisting member 610 can be made of, for example, a known resin material or metal material.
 (変形例4)
 図11に示すように、例えば、カテーテルの本体部110の移動を補助する押込補助部材として、バルーンカテーテル200を利用することも可能である。バルーンカテーテル200を押込補助部材として利用する場合、例えば、カテーテルの本体部110の先端に、バルーン210の先端付近を当接させるための膜材710を取り付けることができる。カテーテルの本体部110を移動させる際、バルーン210の先端を膜材710に接触させつつ、バルーンカテーテル200を押し込むことにより、カテーテルの本体部110を円滑に移動させることが可能になる。なお、膜材710には、ガイドワイヤ300等を挿通させるための貫通孔を設けることができる。また、膜材710は、例えば、公知の樹脂材料で構成することができる。
(Modification 4)
As shown in FIG. 11, for example, the balloon catheter 200 can be used as a pushing assisting member that assists in the movement of the main body 110 of the catheter. When the balloon catheter 200 is used as a pushing assisting member, for example, a membrane material 710 for bringing the vicinity of the distal end of the balloon 210 into contact with the distal end of the main body 110 of the catheter can be attached. When the catheter main body 110 is moved, the catheter main body 110 can be smoothly moved by pushing the balloon catheter 200 while the tip of the balloon 210 is in contact with the membrane material 710. Note that the film material 710 can be provided with a through-hole through which the guide wire 300 or the like is inserted. Further, the film material 710 can be made of, for example, a known resin material.
 (変形例5)
 図12に示すように、例えば、バルーンカテーテルとして、いわゆるパフュージョンバルーンカテーテル200Aを使用することも可能である。パフュージョンバルーンカテーテル200Aを使用することにより、バルーン210を拡張させて薬剤130を塗布している間も血流を確保することが可能になるため、薬剤130を血管Bの目的部位に塗布する処置を長時間に亘って継続することができる。それにより、血管Bの目的部位に対してより確実に薬剤130を塗布することが可能になる。なお、パフュージョンバルーンカテーテル200Aは、医療分野において公知のものを利用することが可能である。
(Modification 5)
As shown in FIG. 12, for example, a so-called perfusion balloon catheter 200A can be used as a balloon catheter. By using the perfusion balloon catheter 200A, it becomes possible to secure blood flow while the balloon 210 is expanded and the drug 130 is applied, so that the drug 130 is applied to the target site of the blood vessel B. Can be continued for a long time. As a result, the drug 130 can be more reliably applied to the target site of the blood vessel B. As the perfusion balloon catheter 200A, a known one in the medical field can be used.
 (変形例6)
 図13、図14には、変形例6に係る本体部110Bの一部を示している。図13(A)および図13(B)は、本体部110Bが備えるスリット127から薬剤を放出させる前後の様子を示す斜視図である。図14(A)および図14(B)は、本体部110Bが備えるスリット127から薬剤を放出させる前後の様子を示す横断面図である。
(Modification 6)
13 and 14 show a part of the main body 110B according to Modification 6. FIGS. 13A and 13B are perspective views showing a state before and after the medicine is released from the slit 127 provided in the main body 110B. 14A and 14B are cross-sectional views showing a state before and after the medicine is released from the slit 127 included in the main body 110B.
 図13(A)および図13(B)に示すように、本体部110Bは、内壁部121と、外壁部123と、内壁部121と外壁部123との間に形成された薬剤保持部125と、薬剤保持部125と本体部110Bの外表面とを連通可能とするように外壁部123に形成されたスリット127と、を有している。 As shown in FIGS. 13 (A) and 13 (B), the main body 110B includes an inner wall 121, an outer wall 123, and a medicine holding part 125 formed between the inner wall 121 and the outer wall 123. And a slit 127 formed in the outer wall portion 123 so that the medicine holding portion 125 and the outer surface of the main body portion 110B can communicate with each other.
 図13(A)に示すように、スリット127は、本体部110の軸方向の一部に形成している。また、図14(A)に示すようにスリット127は、本体部110の周方向の異なる位置に複数個形成している。なお、スリット127が形成される軸方向の位置、スリット127の個数、各スリット127の周方向の間隔等は特に限定されない。 As shown in FIG. 13A, the slit 127 is formed in a part of the main body 110 in the axial direction. As shown in FIG. 14A, a plurality of slits 127 are formed at different positions in the circumferential direction of the main body 110. The position in the axial direction where the slits 127 are formed, the number of the slits 127, the interval in the circumferential direction of the slits 127, etc. are not particularly limited.
 図13(B)および図14(B)には、本体部110Bの一部を拡張させることにより薬剤保持部125から薬剤130を放出した際の様子を示している。術者は、例えば、本体部110Bのルーメン111内でバルーンカテーテル200のバルーン210(図5(Aおよび図5(B)を参照)を拡張させて、スリット127を押し広げることにより、スリット127を介して薬剤保持部125内に保持された薬剤130を本体部110Bの外部へ放出させることができる。また、術者は、図13(A)および図14(A)に示すようにスリット127が押し広げられていない状態では、薬剤保持部125内に保持した薬剤130が本体部110Bから漏洩することを抑制できる。したがって、術者は、血管等の生体管腔内で本体部110Bを移動させている間、薬剤130が意図せずに患者に塗布されることを防止できる。 FIG. 13B and FIG. 14B show a state when the medicine 130 is released from the medicine holding part 125 by expanding a part of the main body part 110B. For example, the surgeon expands the slit 127 by expanding the balloon 210 (see FIGS. 5A and 5B) of the balloon catheter 200 within the lumen 111 of the main body 110B, thereby expanding the slit 127. Thus, the medicine 130 held in the medicine holding part 125 can be released to the outside of the main body part 110B, and the surgeon has a slit 127 as shown in FIGS. In a state where the medicine is not spread, the medicine 130 held in the medicine holding part 125 can be prevented from leaking out from the main body part 110B, so that the surgeon moves the main body part 110B within a living body lumen such as a blood vessel. During this time, the medicine 130 can be prevented from being unintentionally applied to the patient.
 なお、スリット127は、外壁部123に連通可能とするように形成されていればよく、一部が未連通でもよい。また、スリット127は、バルーン210を拡張させて開裂して連通するものでもよい。 In addition, the slit 127 should just be formed so that it can communicate with the outer wall part 123, and a part may be non-communication. Further, the slit 127 may be one that expands the balloon 210 to be opened and communicates.
 (その他の変形例)
 実施形態の説明においては、エネルギー印加部として、バルーンカテーテルを利用した例を説明したが、エネルギー印加部はバルーンカテーテルのみに限定されない。エネルギー印加部としては、例えば、圧力、電気、超音波、電磁波、熱等のエネルギー、またこれらの各エネルギーを同時又は時間差等を設けてカテーテルの本体部に対して付与することにより、薬剤保持部から薬剤を放出させるように構成したデバイス等を利用ことも可能である。カテーテルの本体部は、エネルギー印加部が付与するエネルギーの形態等に応じて、薬剤保持部や薬剤放出部の形態を適宜改変することが可能である。
(Other variations)
In the description of the embodiment, the example in which the balloon catheter is used as the energy application unit has been described. However, the energy application unit is not limited to the balloon catheter. As the energy application unit, for example, energy such as pressure, electricity, ultrasonic waves, electromagnetic waves, heat, etc., and each of these energies is applied to the main body of the catheter simultaneously or with a time difference, etc. It is also possible to use a device configured to release the drug from The main body of the catheter can be appropriately modified in the form of the medicine holding part and the medicine releasing part according to the form of energy applied by the energy applying part.
 また、長尺部材は、生体管腔に挿入可能な部材であればよく、実施形態において説明したカテーテルのような構造のものに限定されることはない。 Further, the long member only needs to be a member that can be inserted into the living body lumen, and is not limited to the structure like the catheter described in the embodiment.
 以上、実施形態および複数の変形例を通じて本発明に係る医療デバイスおよび薬剤の塗布方法を説明したが、本発明は実施形態および各変形例において説明した内容のみに限定されることはなく、特許請求の範囲の記載に基づいて適宜変更することが可能である。 As described above, the medical device and the medicine application method according to the present invention have been described through the embodiment and a plurality of modified examples. However, the present invention is not limited to the contents described in the embodiment and each modified example, and is claimed. It is possible to change appropriately based on the description of the range.
 本出願は、2018年3月23日に出願された日本国特許出願第2018-055981号に基づいており、その開示内容は、参照により全体として引用されている。 This application is based on Japanese Patent Application No. 2018-055981 filed on Mar. 23, 2018, the disclosure of which is incorporated by reference in its entirety.
10 医療デバイス、
100 カテーテル(長尺部材)、
110、110A 本体部、
111 ルーメン、
121 内壁部、
123 外壁部、
125 薬剤保持部、
127 薬剤放出部、
130 薬剤、
200 バルーンカテーテル(エネルギー印加部)、
200A パフュージョンバルーンカテーテル(エネルギー印加部)、
210 バルーン、
220 シャフト、
300 ガイドワイヤ、
410 位置ずれ防止部、
510 マスキング部材、
610 押込補助部材、
710 膜材、
B 血管(生体管腔)。
10 medical devices,
100 catheter (long member),
110, 110A body part,
111 lumens,
121 inner wall,
123 outer wall,
125 drug holder,
127 drug release part,
130 drugs,
200 balloon catheter (energy application part),
200A perfusion balloon catheter (energy application unit),
210 balloon,
220 shaft,
300 guidewire,
410 misalignment prevention unit,
510 masking member,
610 push-in auxiliary member,
710 membrane material,
B Blood vessel (biological lumen).

Claims (11)

  1.  ルーメンを形成する内壁部と、外表面を形成する外壁部と、前記内壁部と前記外壁部との間に設けられ、生体管腔内で放出される薬剤を保持可能な薬剤保持部と、前記外壁部に形成され、前記薬剤を前記薬剤保持部から前記外表面側へ放出可能な薬剤放出部と、を有する長尺状の本体部を備える長尺部材と、
     前記本体部に対してエネルギーを付与することにより、前記薬剤放出部からの前記薬剤の放出を開始させるエネルギー印加部と、を有する医療デバイス。
    An inner wall part forming a lumen, an outer wall part forming an outer surface, a drug holding part provided between the inner wall part and the outer wall part and capable of holding a drug released in a living body lumen; A long member comprising an elongate main body formed on an outer wall and having a drug release part capable of releasing the drug from the drug holding part to the outer surface side;
    A medical device comprising: an energy application unit that starts the release of the drug from the drug release unit by applying energy to the main body unit.
  2.  前記エネルギー印加部は、前記本体部の前記ルーメン内に挿入可能であるとともに前記ルーメン内において拡張することにより前記薬剤放出部から前記薬剤を放出させるバルーンを備えるバルーンカテーテルを有する、請求項1に記載の医療デバイス。 The said energy application part has a balloon catheter provided with the balloon which discharges the said chemical | medical agent from the said chemical | medical agent discharge | release part by expanding in the said lumen | rumen while being able to be inserted in the said lumen | rumen of the said main-body part. Medical devices.
  3.  前記薬剤保持部は、前記本体部の軸方向に沿って延在するとともに前記内壁部と前記外壁部との間に形成された空間部を有する、請求項1または請求項2に記載の医療デバイス。 The medical device according to claim 1, wherein the medicine holding portion has a space portion that extends along the axial direction of the main body portion and is formed between the inner wall portion and the outer wall portion. .
  4.  前記薬剤放出部は、前記薬剤保持部と前記本体部の外表面とを連通するように前記外壁部に形成された貫通孔を有する、請求項1~3のいずれか1項に記載の医療デバイス。 The medical device according to any one of claims 1 to 3, wherein the medicine release section includes a through hole formed in the outer wall section so as to communicate the medicine holding section and the outer surface of the main body section. .
  5.  前記薬剤放出部は、前記薬剤保持部と前記本体部の外表面とを連通可能とするように前記外壁部に形成されたスリットを有する、請求項1~3のいずれか1項に記載の医療デバイス。 The medical medicine according to any one of claims 1 to 3, wherein the medicine discharge section has a slit formed in the outer wall section so as to allow communication between the medicine holding section and the outer surface of the main body section. device.
  6.  前記薬剤保持部に保持された前記薬剤が位置ずれするのを防止する位置ずれ防止部を有する、請求項1~5のいずれか1項に記載の医療デバイス。 The medical device according to any one of claims 1 to 5, further comprising a displacement prevention unit that prevents the medicine held by the medicine holding unit from being displaced.
  7.  前記本体部の軸方向に沿って相対的に移動可能であるとともに、前記本体部の前記外壁部を覆うように配置されることにより、前記薬剤放出部からの前記薬剤の放出を制限するマスキング部材を有する、請求項1~6のいずれか1項に記載の医療デバイス。 A masking member that is relatively movable along the axial direction of the main body and that is disposed so as to cover the outer wall of the main body so as to limit the release of the medicine from the medicine discharge portion. The medical device according to any one of claims 1 to 6, comprising:
  8.  前記本体部を生体管腔内において移動させる際に前記本体部の押し込みを補助する押込補助部材を有する、請求項1~7のいずれか1項に記載の医療デバイス。 The medical device according to any one of claims 1 to 7, further comprising a pushing assisting member for assisting pushing of the main body when the main body is moved in a living body lumen.
  9.  内壁部と外壁部との間に設けられた薬剤保持部に薬剤を保持した状態の長尺状の本体部を備える長尺部材を用意するステップと、
     前記薬剤保持部からの前記薬剤の放出を開始するためのエネルギーを付与可能なエネルギー印加部を用意するステップと、
     前記本体部を生体管腔内に導入するステップと、
     前記本体部を前記生体管腔内に導入した状態で、前記エネルギー印加部により、前記本体部の任意の位置に対して選択的にエネルギーを付与することにより、前記薬剤保持部から前記薬剤を放出させて、前記生体管腔の塗布対象部位に対して前記薬剤を塗布するステップと、を有する薬剤の塗布方法。
    Preparing an elongate member comprising an elongated main body in a state of holding a drug in a drug holding part provided between an inner wall part and an outer wall part;
    Preparing an energy application unit capable of applying energy for initiating release of the drug from the drug holding unit;
    Introducing the body portion into the body lumen;
    With the main body portion introduced into the living body lumen, the energy is applied to the arbitrary position of the main body portion by the energy application portion, thereby releasing the medicine from the medicine holding portion. And applying the medicine to the application target site of the living body lumen.
  10.  前記薬剤を塗布するステップを終えた後に前記エネルギー印加部を前記本体部に対して相対的に移動させるステップと、
     前記エネルギー印加部により、前記本体部に対してエネルギーを付与し、前記薬剤が塗布された部位とは異なる部位に対して前記薬剤を塗布するステップと、を有する請求項9に記載の薬剤の塗布方法。
    Moving the energy application part relative to the body part after finishing the step of applying the medicine;
    The medicine application according to claim 9, further comprising: applying energy to the body portion by the energy application section, and applying the medicine to a site different from a site to which the medicine is applied. Method.
  11.  前記薬剤の塗布は、前記エネルギー印加部が備えるバルーンカテーテルを前記本体部のルーメン内に挿入し、前記バルーンカテーテルが備えるバルーンを拡張させることにより行う、請求項9または請求項10に記載の薬剤の塗布方法。 The drug application according to claim 9 or 10, wherein the drug application is performed by inserting a balloon catheter provided in the energy application unit into a lumen of the main body part and expanding a balloon provided in the balloon catheter. Application method.
PCT/JP2019/012162 2018-03-23 2019-03-22 Medical device and method of applying medicament WO2019182131A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020507944A JP7214715B2 (en) 2018-03-23 2019-03-22 medical device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018055981 2018-03-23
JP2018-055981 2018-03-23

Publications (1)

Publication Number Publication Date
WO2019182131A1 true WO2019182131A1 (en) 2019-09-26

Family

ID=67986446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/012162 WO2019182131A1 (en) 2018-03-23 2019-03-22 Medical device and method of applying medicament

Country Status (2)

Country Link
JP (1) JP7214715B2 (en)
WO (1) WO2019182131A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5634899A (en) * 1993-08-20 1997-06-03 Cortrak Medical, Inc. Simultaneous cardiac pacing and local drug delivery method
JPH10505767A (en) * 1994-09-13 1998-06-09 ローカルメッド インコーポレイテッド Catheter sleeve and method of using the same
JP2008535578A (en) * 2005-04-08 2008-09-04 カーリン メディカル インコーポレイテッド Adjustable infusion catheter
JP2011513005A (en) * 2008-03-06 2011-04-28 ボストン サイエンティフィック サイムド,インコーポレイテッド Balloon catheter device with sheath coating
US20130310734A1 (en) * 2012-05-21 2013-11-21 Sinuwave Technologies, Inc. Catheter for photodynamic therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5634899A (en) * 1993-08-20 1997-06-03 Cortrak Medical, Inc. Simultaneous cardiac pacing and local drug delivery method
JPH10505767A (en) * 1994-09-13 1998-06-09 ローカルメッド インコーポレイテッド Catheter sleeve and method of using the same
JP2008535578A (en) * 2005-04-08 2008-09-04 カーリン メディカル インコーポレイテッド Adjustable infusion catheter
JP2011513005A (en) * 2008-03-06 2011-04-28 ボストン サイエンティフィック サイムド,インコーポレイテッド Balloon catheter device with sheath coating
US20130310734A1 (en) * 2012-05-21 2013-11-21 Sinuwave Technologies, Inc. Catheter for photodynamic therapy

Also Published As

Publication number Publication date
JP7214715B2 (en) 2023-01-30
JPWO2019182131A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
AU2022204890B2 (en) Controlled porosity devices for tissue treatments, methods of use, and methods of manufacture
CN107308536B (en) Balloon catheter including a drug delivery sheath
AU2021261968B2 (en) Multiple inflation endovascular medical device
EP3838327B1 (en) Balloon catheter with transient radiopaque marking
JP7223820B2 (en) medical device
WO2019182131A1 (en) Medical device and method of applying medicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19772238

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020507944

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19772238

Country of ref document: EP

Kind code of ref document: A1